This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice (UK)

This study is currently recruiting participants.
See Contacts and Locations
Verified July 2017 by Bayer
Sponsor:
Collaborator:
Janssen Research & Development, LLC
Information provided by (Responsible Party):
Bayer
ClinicalTrials.gov Identifier:
NCT01947998
First received: September 11, 2013
Last updated: July 10, 2017
Last verified: July 2017
  Purpose
This prospective cohort study will provide information about: characteristics of Rivaroxaban use in patients who are prescribed Rivaroxaban for the first time compared to patients who are prescribed Warfarin for the first time, the occurrence of intracranial haemorrhage, gastrointestinal and urogenital bleeding, and the occurrence of non-infective liver disease.

Condition Intervention
Pulmonary Embolism Drug: Rivaroxaban (Xarelto, Bay59-7939) Drug: Warfarin

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Proposed Pharmacoepidemiological Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Pratice in the United Kingdom.

Resource links provided by NLM:


Further study details as provided by Bayer:

Primary Outcome Measures:
  • Major bleedings: Intracranial haemorrhage, Gastrointestinal bleeding and Urogenital bleeding [ Time Frame: The two cohorts will be followed up from the index date until 12 months after the end of the extended enrollment period for potential outcomes ]
  • Drug utilization pattern [ Time Frame: The two cohorts will be followed up from the index date until 12 months after the end of the extended enrollment period for potential outcomes ]

Secondary Outcome Measures:
  • Non-infective liver disease [ Time Frame: The two cohorts will be followed up from the index date until 12 months after the end of the extended enrolment period for potential outcomes ]
  • Effectiveness outcomes: Deep vein thrombosis and Pulmonary embolism, Ischaemic stroke, Myocardial infarction, Death [ Time Frame: The two cohorts will be followed up from the index date until 12 months after the end of the extended enrolment period for potential outcomes. ]

Estimated Enrollment: 20000
Actual Study Start Date: December 22, 2011
Estimated Study Completion Date: December 31, 2019
Estimated Primary Completion Date: December 31, 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Group 1
Rivaroxaban
Drug: Rivaroxaban (Xarelto, Bay59-7939)
Patients who have been prescribed Rivaroxaban for the first time, divided in two subgroups: Naïve and Non Naïve. The Non Naïve are also divided in two subgroups: Recent switchers and Distant switchers.
Group 2
Warfarin
Drug: Warfarin
Patients who have been prescribed Warfarin for the first time, divided in two subgroups: Naïve and Non Naïve. The Non Naïve are also divided in two subgroups: Recent switchers and Distant switchers.

  Eligibility

Ages Eligible for Study:   2 Years to 89 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All male and female patient aged 2 to 89 years who have been enrolled in the database (GePaRD) for at least 1 year.
Criteria

Inclusion Criteria:

  • Patients between 2 and 89 years, who have been prescribed for the first time either Rivaroxaban or Warfarin.

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01947998

Contacts
Contact: Bayer Clinical Trials Contact clinical-trials-contact@bayer.com

Locations
United Kingdom
Recruiting
Many Locations, United Kingdom
Sponsors and Collaborators
Bayer
Janssen Research & Development, LLC
Investigators
Study Director: Bayer Study Director Bayer
  More Information

Additional Information:
Responsible Party: Bayer
ClinicalTrials.gov Identifier: NCT01947998     History of Changes
Other Study ID Numbers: 16647
EUPAS11299 ( Registry Identifier: ENCEPP )
Study First Received: September 11, 2013
Last Updated: July 10, 2017

Keywords provided by Bayer:
Rivaroxaban,
Pulmonary Embolism,
Venous Thrombosis,
Venous Thromboembolism,
Acute Coronary Syndrome,
Intracranial Hemorrhages,
Gastrointestinal Hemorrhage,
Warfarin

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Warfarin
Rivaroxaban
Anticoagulants
Factor Xa Inhibitors
Antithrombins
Serine Proteinase Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on July 26, 2017